Medicare Enrolled

Dr. Sampath Manickam, M.D.

Rheumatology · Sarasota, FL
Practice pattern: Mixed Practice— Diverse clinical practice across multiple procedure types
Low-engagement
8383 S TAMIAMI TRL UNIT 115, Sarasota, FL 34238
9414974069
In practice since 2012 (13 years)
NPI: 1770845711 verify on NPPES ↗
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Manickam from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Manickam? Request a correction or review of any data shown here. Provider portal →

What this data tells you about Dr. Manickam

Dr. Sampath Manickam is a rheumatology in Sarasota, FL, with 13 years in practice. Based on federal Medicare data, Dr. Manickam performed 72,361 Medicare services across 1,537 unique beneficiaries.

Between the years covered by Open Payments, Dr. Manickam received a total of $26,508 from 48 pharmaceutical and/or device companies across 826 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in rheumatology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.

The Data Coverage level for Dr. Manickam is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.

✓ 13 years in practice▲ Top 32% volume in FL$ $26,508 industry payments

Medicare Practice Summary

Medicare Utilization ↗
72,361
Medicare services
Top 32% in FL for rheumatology
1,537
Unique beneficiaries
$11
Avg. Medicare payment
Medicare patients only (65+ / disabled) · Not a quality rating · How to read this →
~5,566 Medicare services per year of practice

Top procedures by volume

Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.

ProcedureVolumeAvg. paidAvg. submitted
Certolizumab injection (Cimzia)41,600$4$10
Golimumab infusion (Simponi Aria)12,385$11$27
Denosumab injection (Prolia/Xgeva)7,800$18$47
Abatacept infusion (Orencia)5,400$34$86
Infliximab infusion (Remicade)3,080$26$68
Office visit, established patient (30-39 min)447$93$264
Office visit, established patient (20-29 min)257$63$187
Drug injection, under skin or into muscle254$10$30
Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less155$45$131
Blood draw (venipuncture)147$8$17
Complete blood count (CBC) with differential122$8$16
Comprehensive metabolic blood panel120$10$21
Office visit, established patient, complex (40-54 min)120$130$371
Steroid injection (triamcinolone)113$1$2
Administration of chemotherapy into vein, 1 hour or less83$96$268
C-reactive protein test (inflammation marker)69$5$10
New patient office visit, complex (60-74 min)69$152$459
Sed rate test (inflammation marker)65$3$5
Joint injection, major joint25$60$137
New patient office visit (45-59 min)20$104$347
Uric acid level test18$4$9
Hepatitis c antibody screening, for individual at high risk and other covered indication(s)12$42$93
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
29.0% high complexity
68.9% medium
2.0% routine

Industry Payment Transparency

Open Payments through 2024 ↗
$26,508
Total received (2018-2024)
Avg $3,787/year across 7 years
Top 17% in FL for rheumatology
48
Companies
826
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →

Payment profile

Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.

Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$20,527 (77.4%)
Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$5,749 (21.7%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$231 (0.9%)

Payment trend by year

Annual totals from pharmaceutical and medical device companies.

2024
$2,820
2023
$2,907
2022
$8,706
2021
$1,695
2020
$1,935
2019
$4,703
2018
$3,743

Payments by company (2024)

Consulting
Speaking
Meals & Travel
Research
Janssen Biotech, Inc.
$6,639
Amgen Inc.
$3,705
PFIZER INC.
$1,828
ABBVIE INC.
$1,716
AbbVie, Inc.
$1,601
Lilly USA, LLC
$1,583
UCB, Inc.
$1,064
Novartis Pharmaceuticals Corporation
$975
AstraZeneca Pharmaceuticals LP
$950
Radius Health, Inc.
$898
GlaxoSmithKline, LLC.
$717
AbbVie Inc.
$607
E.R. Squibb & Sons, L.L.C.
$519
Celgene Corporation
$481
Horizon Therapeutics plc
$361
Aurinia Pharma U.S., Inc.
$357
Janssen Scientific Affairs, LLC
$336
Actelion Pharmaceuticals US, Inc.
$179
Mallinckrodt Hospital Products Inc.
$178
Genentech USA, Inc.
$167
Boehringer Ingelheim Pharmaceuticals, Inc.
$153
GENZYME CORPORATION
$134
Mallinckrodt Enterprises LLC
$124
Fresenius Kabi USA, LLC
$109
Antares Pharma, Inc.
$107
SOBI, INC
$100
Relievant Medsystems, Inc.
$87
Ferring Pharmaceuticals Inc.
$84
United Therapeutics Corporation
$81
ANI Pharmaceuticals, Inc.
$77
Organon Llc
$67
Kowa Pharmaceuticals America, Inc.
$62
Sobi, Inc
$57
Exact Sciences Corporation
$51
Kiniksa Pharmaceuticals International, plc
$50
Sandoz Inc.
$41
Exeltis, USA Inc.
$38
Egalet US Inc
$34
Horizon Pharma plc
$33
Mylan Institutional Inc.
$28
SANOFI-AVENTIS U.S. LLC
$22
Mallinckrodt LLC
$21
Bayer Healthcare Pharmaceuticals Inc.
$20
Phathom Pharmaceuticals, Inc.
$18
Biohaven Pharmaceutical Holding Company Ltd.
$14
BIODELIVERY SCIENCES INTERNATIONAL, INC.
$12
Janssen Pharmaceuticals, Inc
$11
MEDEXUS PHARMA, INC.
$11
Top 3 companies account for 45.9% of total payments
Associated products mentioned in payments ›
ACTHAR · AIRSUPRA · Actemra · Arcalyst · BELBUCA · BENLYSTA · Bimzelx · COSENTYX · CYLTEZO · Cimzia · Cologuard Collection Kit · DUEXIS · EUFLEXXA · EVENITY · Enbrel · FORTEO · HADLIMA · HUMIRA · HYRIMOZ · Humira · IDACIO · INFLECTRA · Intracept · KEVZARA · KINERET · KRYSTEXXA · Kerendia · Kineret · LEQVIO · LUPKYNIS · MOUNJARO · NONE · NURTEC ODT · OFEV · OLUMIANT · OPSUMIT · ORENCIA · OTREXUP · Otezla · Otrexup · PAXLOVID · PENNSAID · PREVNAR 20 · PURIFIED CORTROPHIN GEL · Prolia · QULIPTA · RAYOS · REMICADE · RINVOQ · Rasuvo · Rinvoq · Rituxan · SAPHNELO · SEGLENTIS · SHINGRIX · SIMPONI · SIMPONI ARIA · SKYRIZI · SPRIX · STELARA · SYNVISC-ONE · Seglentis · TALTZ · TAVNEOS · TRELEGY ELLIPTA · TREMFYA · Tavneos · Tymlos · UBRELVY · VOQUEZNA · XARELTO · XELJANZ · XYOSTED
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →

Most payments (77%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.

Equivalent to $37 per 100 Medicare services performed
Looking for a rheumatology in Sarasota?
Compare rheumatologys in the Sarasota area by procedure volume, costs, and industry payment transparency.
Browse rheumatologys nearby

Geographic Context

Rheumatologys within 10 mi
25
Per 100K population
5.6
County median income
$80,633
Nearest hospital
HCA FLORIDA SARASOTA DOCTORS HOSPITAL
3.1 mi

Data Sources

Provider Registry NPPESWeekly updates
Medicare Enrollment PECOSMonthly updates
Practice Data Medicare Util.Annual (CY lag)
Industry Payments Open PaymentsCY 2024
Disciplinary History— Not publicN/A

This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →

Summary

Dr. Manickam is a mixed practice specialist, with moderate Medicare volume, and high industry engagement (low-engagement, top 17%).

This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →

Frequently Asked Questions

Is Dr. Manickam experienced with certolizumab injection (cimzia)?
Based on Medicare claims data, Dr. Manickam performed 41,600 certolizumab injection (cimzia) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Manickam receive payments from pharmaceutical companies?
Yes. Dr. Manickam received a total of $26,508 from 48 companies across 826 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Manickam's costs compare to other rheumatologys in Sarasota?
Dr. Manickam's average Medicare payment per service is $11. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Manickam) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
About this page

All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.

This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.

Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology

Data Disclaimer — Data sourced from the Centers for Medicare & Medicaid Services (CMS): National Plan and Provider Enumeration System (NPPES), Open Payments program, Medicare Provider Utilization and Payment Data, and Provider Enrollment & Certification data (PECOS). Published under the Freedom of Information Act (FOIA). This website is not affiliated with, endorsed by, or authorized by CMS, HHS, or the U.S. Government. Data may contain errors as reported to CMS by providers and reporting entities. Payments from industry are legal and do not indicate wrongdoing. Medicare data reflects only patients aged 65+ or those with qualifying disabilities. For corrections, contact CMS directly. This information does not constitute medical advice and should not be used as the sole basis for choosing a healthcare provider. Procedure descriptions use plain language and do not reference CPT® codes, which are copyrighted by the American Medical Association. Full methodology → · Report a data error → · Privacy policy →